We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Study Compares Survival Outcomes Using Different Cancer Staging Methods

By MedImaging International staff writers
Posted on 05 Oct 2016
Researchers in the Netherlands have compared five-year survival rates for mediastinal nodal lung cancer staging, after treatment with endosonography or mediastinoscopy.

The results of the study were published in the September 13, 2016, issue of the journal JAMA. Accurate mediastinal nodal staging directs therapy, and provides prognostic value during the management of Non-Small Cell Lung Cancer (NSCLC).

Image: An artist’s rendition showing lung cancer (Photo courtesy of Dreamstime).
Image: An artist’s rendition showing lung cancer (Photo courtesy of Dreamstime).

The Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial compared an endosonographic staging strategy with surgical staging using mediastinoscopy. Endosonography combines endobronchial, and transesophageal ultrasound, and is followed up using mediastinoscopy, in case the results are negative.

The researchers evaluated 241 patients suffering from potentially resectable NSCLC, in 4 tertiary referral centers. There were 123 patients randomized to endosonographic staging, and 118 patients to surgical staging. The researchers found that endosonography was significantly more sensitive (97%) during the diagnosis of mediastinal nodal metastases, compared to surgical staging (79%).

The five-year survival rate was 35% for both the endosonographic and surgical strategies. The estimated median survival for the endosonographic strategy was 31 months compared to 33 months for the surgical strategy. The researchers concluded that improved mediastinal staging could ensure better treatment for a larger number of patients, and could increase the long-term survival rates of the patients.

Jouke T. Annema, MD, PhD, Academic Medical Center, Amsterdam (Amsterdam, Netherlands), said, "Why did improved mediastinal staging not lead to improved survival? Missing data occurred in less than 2 percent and therefore are an unlikely source of bias. However, ASTER was powered to detect a difference in diagnostic sensitivity, not survival, as reflected by the wide confidence intervals. If a survival difference between the strategies exists, it is likely to be small and a larger sample size may be needed to detect it. However, randomized trials to detect a survival difference based on staging strategy are not likely to be conducted as the endosonographic strategy is now advised in clinical guidelines."

Related Links:
Academic Medical Center


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Computed Tomography (CT) Scanner
Aquilion Serve SP
New
CT Phantom
CIRS Model 610 AAPM CT Performance Phantom
New
Breast Imaging Workstation
SecurView

Latest Ultrasound News

Groundbreaking Technology Enables Precise, Automatic Measurement of Peripheral Blood Vessels

Deep Learning Advances Super-Resolution Ultrasound Imaging

Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection